Literature DB >> 21175212

Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex.

Claudia Binda1, Milagros Aldeco, Andrea Mattevi, Dale E Edmondson.   

Abstract

The binding of zonisamide to purified, recombinant monoamine oxidases (MAOs) has been investigated. It is a competitive inhibitor of human MAO B (K(i) = 3.1 ± 0.3 μM), of rat MAO B (K(i) = 2.9 ± 0.5 μM), and of zebrafish MAO (K(i) = 30.8 ± 5.3 μM). No inhibition is observed with purified human or rat MAO A. The 1.8 Å structure of the MAO B complex demonstrates that it binds within the substrate cavity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175212      PMCID: PMC3071873          DOI: 10.1021/jm101359c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Zonisamide: aspects in neuroprotection.

Authors:  Thomas W Rösler; Oscar Arias-Carrión; Günter U Höglinger
Journal:  Exp Neurol       Date:  2010-05-04       Impact factor: 5.330

2.  High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae.

Authors:  Min Li; Frantisĕk Hubálek; Paige Newton-Vinson; Dale E Edmondson
Journal:  Protein Expr Purif       Date:  2002-02       Impact factor: 1.650

Review 3.  Safinamide in the treatment of Parkinson's disease.

Authors:  Anthony H V Schapira
Journal:  Expert Opin Pharmacother       Date:  2010-09       Impact factor: 3.889

4.  High-level expression of human liver monoamine oxidase B in Pichia pastoris.

Authors:  P Newton-Vinson; F Hubalek; D E Edmondson
Journal:  Protein Expr Purif       Date:  2000-11       Impact factor: 1.650

5.  Effects of zonisamide on dopaminergic system.

Authors:  M Okada; S Kaneko; T Hirano; K Mizuno; T Kondo; K Otani; Y Fukushima
Journal:  Epilepsy Res       Date:  1995-11       Impact factor: 3.045

6.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

7.  Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures.

Authors:  Claudia Binda; Min Li; Frantisek Hubalek; Nadia Restelli; Dale E Edmondson; Andrea Mattevi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

8.  Characterization of detergent purified recombinant rat liver monoamine oxidase B expressed in Pichia pastoris.

Authors:  Anup K Upadhyay; Dale E Edmondson
Journal:  Protein Expr Purif       Date:  2008-03-10       Impact factor: 1.650

9.  Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities.

Authors:  H Uno; M Kurokawa; Y Masuda; H Nishimura
Journal:  J Med Chem       Date:  1979-02       Impact factor: 7.446

Review 10.  Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.

Authors:  M Murata
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  12 in total

1.  The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition.

Authors:  Erika M Milczek; Claudia Binda; Stefano Rovida; Andrea Mattevi; Dale E Edmondson
Journal:  FEBS J       Date:  2011-11-03       Impact factor: 5.542

2.  Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson's disease.

Authors:  Jacob Boos; Ahmed Shubbar; Werner J Geldenhuys
Journal:  Med Chem Res       Date:  2021-04-09       Impact factor: 2.351

3.  Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells.

Authors:  Vedat Ali Yürekli; Semih Gürler; Mustafa Nazıroğlu; Abdülhadi Cihangir Uğuz; Hasan Rifat Koyuncuoğlu
Journal:  Cell Mol Neurobiol       Date:  2012-11-15       Impact factor: 5.046

4.  Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

Authors:  Pablo Duarte; Antonio Cuadrado; Rafael León
Journal:  Handb Exp Pharmacol       Date:  2021

5.  A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.

Authors:  Baldeep Kumar; Bikash Medhi; Manish Modi; Biman Saikia; Savita Verma Attri; Ajay Patial
Journal:  Inflammopharmacology       Date:  2018-04-11       Impact factor: 4.473

6.  Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies.

Authors:  Guillermo Moya-Alvarado; Osvaldo Yañez; Nicole Morales; Angélica González-González; Carlos Areche; Marco Tulio Núñez; Angélica Fierro; Olimpo García-Beltrán
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

7.  Why p-OMe- and p-Cl-β-Methylphenethylamines Display Distinct Activities upon MAO-B Binding.

Authors:  Angélica Fierro; Dale E Edmondson; Cristian Celis-Barros; Marco Rebolledo-Fuentes; Gerald Zapata-Torres
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

Review 8.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

9.  Computational Drug Target Screening through Protein Interaction Profiles.

Authors:  Santiago Vilar; Elías Quezada; Eugenio Uriarte; Stefano Costanzi; Fernanda Borges; Dolores Viña; George Hripcsak
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

Review 10.  Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.

Authors:  Neeta D Grover; Ramachandra P Limaye; Dilip V Gokhale; Tatyasaheb R Patil
Journal:  Indian J Pharmacol       Date:  2013 Nov-Dec       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.